1. Homepage
  2. Equities
  3. United States
  4. Nasdaq
  5. Centogene N.V.
  6. Summary
    CNTG   NL0014040206

CENTOGENE N.V.

(CNTG)
  Report
Delayed Nasdaq  -  04:00 2022-08-05 pm EDT
1.570 USD   -2.48%
08/03CENTOGENE N : Company presentation - August 2022
PU
07/18SVB Securities Adjusts Centogene's Price Target to $6 from $10, Keeps Outperform Rating
MT
07/15CENTOGENE N : Reports First Quarter 2022 Financial Results - Form 6-K
PU
 SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Quotes 5-day view   Delayed Quote. Delayed Nasdaq
08/01/2022 08/02/2022 08/03/2022 08/04/2022 08/05/2022 Date
1.4(c) 1.47(c) 1.55(c) 1.61(c) 1.57(c) Last
26 016 28 646 14 365 14 551 14 133 Volume
+0.72% +5.00% +5.44% +3.87% -2.48% Change
More quotes
Estimated financial data (e)
Sales 2022 49,9 M 50,7 M 50,7 M
Net income 2022 -33,0 M -33,5 M -33,5 M
Net Debt 2022 - - -
P/E ratio 2022 -1,10x
Yield 2022 -
Sales 2023 57,4 M 58,3 M 58,3 M
Net income 2023 -35,4 M -35,9 M -35,9 M
Net Debt 2023 - - -
P/E ratio 2023 -1,06x
Yield 2023 -
Capitalization 41,9 M 42,5 M 42,5 M
Capi. / Sales 2022 0,84x
Capi. / Sales 2023 0,73x
Nbr of Employees 808
Free-Float 44,9%
More Financials
Company
Centogene BV is a Germany-based company engaged in the rare disease market. It focuses on transforming clinical, genetic and biochemical data into medical solutions for patients, physicians and pharmaceutical companies. The Company provides the full spectrum of methods and technology for human genetics analysis. It develops a rare disease platform based on its real-world data repository with over 2.0 billion... 
More about the company
Ratings of Centogene N.V.
Trading Rating :  -
Investor Rating : 
ESG Refinitiv : 
B-
More Ratings
All news about CENTOGENE N.V.
08/03CENTOGENE N : Company presentation - August 2022
PU
07/18SVB Securities Adjusts Centogene's Price Target to $6 from $10, Keeps Outperform Rating
MT
07/15CENTOGENE N : Reports First Quarter 2022 Financial Results - Form 6-K
PU
07/15Centogene N.V. Reports Earnings Results for the First Quarter Ended March 31, 2022
CI
07/15CENTOGENE Reports First Quarter 2022 Financial Results
GL
07/15CENTOGENE Reports First Quarter 2022 Financial Results
AQ
07/15Centogene N.V. Reaffirms Earnings Guidance for the Year 2022
CI
06/27CENTOGENE N : Announces Shareholder Approval of All Resolutions at 2022 Annual General Mee..
PU
06/27Centogene Appoints Miguel Coego Rios as CFO
MT
06/27CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meet..
GL
06/27CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
GL
06/27CENTOGENE Announces Shareholder Approval of All Resolutions at 2022 Annual General Meet..
AQ
06/27CENTOGENE Announces Appointment of Miguel Coego Rios as Chief Financial Officer
AQ
06/27Centogene N.V. Announces Appointment of Miguel Coego Rios as Managing Director
CI
06/27Centogene N.V. Announces Appointment of Miguel Coego Rios as Chief Financial Officer
CI
More news
News in other languages on CENTOGENE N.V.
07/15Centogene N.V. annonce ses résultats pour le premier trimestre clos le 31 mars 2022
07/15Centogene N.V. réaffirme ses prévisions de bénéfices pour l'année 2022
06/27Centogene N.V. annonce la nomination de Miguel Coego Rios au poste de directeur général
05/03Centogene N.V. annonce la démission de Volkmar Weckesser en tant que directeur de l'inf..
04/28Centogene N.V. et Takeda étendent leur partenariat d'accès au marché et d'expansion pou..
More news
Analyst Recommendations on CENTOGENE N.V.
More recommendations
Chart CENTOGENE N.V.
Duration : Period :
Centogene N.V. Technical Analysis Chart | MarketScreener
Full-screen chart
Technical analysis trends CENTOGENE N.V.
Short TermMid-TermLong Term
TrendsBearishBearishBearish
Income Statement Evolution
Consensus
Sell
Buy
Mean consensus BUY
Number of Analysts 1
Last Close Price 1,55 €
Average target price 5,95 €
Spread / Average Target 285%
EPS Revisions
Managers and Directors
Kim Stratton Chief Executive Officer & Managing Director
Miguel Coego Rios Chief Financial Officer & Managing Director
Peer Michael Schatz Chairman-Supervisory Board
Michael Dost Senior Director-Information Technology Operations
Krishna Kumar Kandaswamy Director-Research & Development Bioinformatics
Sector and Competitors
1st jan.Capi. (M$)
CENTOGENE N.V.-69.97%43
MODERNA, INC.-26.44%73 092
IQVIA HOLDINGS INC.-16.94%43 781
LONZA GROUP AG-26.44%43 083
SEAGEN INC.13.72%32 426
ALNYLAM PHARMACEUTICALS, INC.28.89%26 235